In defense of pharmacoepidemiology - Embracing the yin and yan of drug research

被引：128
作者：
Avorn, Jerry [1 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 357卷 / 22期
关键词：
D O I：
10.1056/NEJMp0706892
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2219 / 2221
页数：3
相关论文
共 5 条
[1]   Hormone replacement therapy, heart disease, and other considerations [J].
Barrett-Connor, E ;
Grady, D .
ANNUAL REVIEW OF PUBLIC HEALTH, 1998, 19 :55-72
[2]  
HARRIS G, 2007, NY TIMES 0920
[3]  
MATHEWS AW, 2007, WALL STREET J 1105
[4]   Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results [J].
Schneeweiss, Sebastian ;
Patrick, Amanda R. ;
Sturmer, Til ;
Brookhart, M. Alan ;
Avorn, Jerry ;
Maclure, Malcolm ;
Rothman, Kenneth J. ;
Glynn, Robert J. .
MEDICAL CARE, 2007, 45 (10) :S131-S142
[5]   Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial [J].
Shepherd, J ;
Blauw, GJ ;
Murphy, MB ;
Bollen, ELEM ;
Buckley, BM ;
Cobbe, SM ;
Ford, I ;
Gaw, A ;
Hyland, M ;
Jukema, JW ;
Kamper, AM ;
Macfarlane, PW ;
Meinders, AE ;
Norrie, J ;
Packard, CJ ;
Perry, IJ ;
Stott, DJ ;
Sweeney, BJ ;
Twomey, C ;
Westendorp, RGJ .
LANCET, 2002, 360 (9346) :1623-1630
1